Dabigatran-associate Acute Generalized Exanthematous Pustulosis (AGEP) in a psoriatic patients undergoing Ixekizumab and its pathogenetic mechanism
Articolo
Data di Pubblicazione:
2019
Citazione:
Dabigatran-associate Acute Generalized Exanthematous Pustulosis (AGEP) in a psoriatic patients undergoing Ixekizumab and its pathogenetic mechanism / K. Schrom, A. Pacifico, R.R. Conic, P.D. Pigatto, P. Malagoli, A. Morrone, R. Finelli, N.L. Bragazzi, G. Damiani. - In: DERMATOLOGIC THERAPY. - ISSN 1396-0296. - 32:5(2019 Sep), pp. e13018.1-e13018.3. [10.1111/dth.13018]
Abstract:
Dabigatran is a broad used new anticoagulant that recently was described to trigger pustular psoriasis. We describe a 49-year-old Caucasian male with psoriasis that after switching from warfarin to dabigatran developed acute generalised exanthematous pustulosis (AGEP). Remarkably we hypothesized a mechanism based increased lipid peroxidation via carboxilesterse-1. In conclusion, higher awareness should be used in patients with inflammatory skin manifestations that undergo new oral anticoagulants.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
Dabigatran; Acute generalised exanthematous pustulosis; Carboxilesterase-1
Elenco autori:
K. Schrom, A. Pacifico, R.R. Conic, P.D. Pigatto, P. Malagoli, A. Morrone, R. Finelli, N.L. Bragazzi, G. Damiani
Link alla scheda completa: